MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Anika Therapeutics DSO Ratio 2011-2026 | ANIK
Annual DSO Ratio Anika Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.3 | 75.3 | 66.6 | 66 | 73.5 | 71.8 | 76.7 | 97.4 | 85 | 59.3 | 91.1 | 110 | 97.5 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 110 | 59.3 | 80.6 |
Quarterly DSO Ratio Anika Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75.7 | 74.3 | 79.5 | - | 95.9 | 97.8 | 107 | - | - | 69.4 | 36.9 | - | - | - | 37.1 | - | 71.3 | 66.9 | 67.3 | 67.3 | 69.4 | 71.7 | 60.8 | 70.7 | 70.9 | 69.2 | 80.9 | 70.3 | 70.8 | 62.1 | 95.7 | 74 | 80 | 65 | 100 | 87.7 | 97.7 | 94.7 | 101 | 64 | 83.4 | 86.3 | 114 | 67.3 | 71 | 59.6 | 48.1 | 80.5 | 96.3 | 82.1 | 120 | 86.6 | 133 | 99.8 | 123 | 85.6 | 85.6 | 97.8 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 133 | 36.9 | 80.8 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B |  USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
58.1 | $ 330.34 | 3.6 % | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Evogene Ltd.
EVGN
|
30 | $ 0.79 | 1.22 % | $ 27.9 M |  Israel |
 |
Фармсинтез
LIFE
|
209 | - | - | - |  Russia |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.89 | -4.33 % | $ 4.85 M | China |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Teligent, Inc.
TLGT
|
90.7 | - | -13.85 % | $ 16.1 M | USA |
 |
AbbVie
ABBV
|
258 | $ 206.69 | -1.01 % | $ 366 B | USA |
 |
Aquestive Therapeutics
AQST
|
103 | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Viela Bio, Inc.
VIE
|
169 | - | - | $ 2.91 B | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.39 | -3.69 % | $ 1.01 B | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Ardelyx
ARDX
|
58 | $ 5.97 | 0.51 % | $ 1.44 B | USA |
 |
Genmab A/S
GMAB
|
97.9 | $ 27.75 | 0.91 % | $ 17.6 B |  Danmark |
 |
Akebia Therapeutics
AKBA
|
62.9 | $ 1.32 | -4.35 % | $ 339 M | USA |